JP7808733B2 - 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物 - Google Patents
置換オキソイソインドリニルピペリジン－２，６－ジオン化合物Info
- Publication number
- JP7808733B2 JP7808733B2 JP2025528339A JP2025528339A JP7808733B2 JP 7808733 B2 JP7808733 B2 JP 7808733B2 JP 2025528339 A JP2025528339 A JP 2025528339A JP 2025528339 A JP2025528339 A JP 2025528339A JP 7808733 B2 JP7808733 B2 JP 7808733B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- carbamate
- isoindol
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363582266P | 2023-09-13 | 2023-09-13 | |
| US63/582,266 | 2023-09-13 | ||
| PCT/US2024/046299 WO2025059245A1 (en) | 2023-09-13 | 2024-09-12 | Substituted oxoisoindolinyl piperidine-2,6-dione compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026500094A JP2026500094A (ja) | 2026-01-06 |
| JP7808733B2 true JP7808733B2 (ja) | 2026-01-29 |
Family
ID=92931770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025528339A Active JP7808733B2 (ja) | 2023-09-13 | 2024-09-12 | 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250084056A1 (da) |
| EP (1) | EP4587429B1 (da) |
| JP (1) | JP7808733B2 (da) |
| KR (1) | KR20250068738A (da) |
| AR (1) | AR133800A1 (da) |
| CO (1) | CO2026002534A2 (da) |
| DK (1) | DK4587429T3 (da) |
| FI (1) | FI4587429T3 (da) |
| LT (1) | LT4587429T (da) |
| MA (1) | MA72090B1 (da) |
| PT (1) | PT4587429T (da) |
| TW (1) | TW202525792A (da) |
| WO (1) | WO2025059245A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120441535B (zh) * | 2025-07-08 | 2025-09-30 | 苏州国匡医药科技有限公司 | 一种含炔基的gspt1降解剂及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022152822A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| WO2023059609A1 (en) | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023069720A1 (en) | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (da) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP3672939A1 (en) | 2017-08-21 | 2020-07-01 | Celgene Corporation | Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate |
-
2024
- 2024-09-12 FI FIEP24782711.6T patent/FI4587429T3/fi active
- 2024-09-12 LT LTEPPCT/US2024/046299T patent/LT4587429T/lt unknown
- 2024-09-12 TW TW113134636A patent/TW202525792A/zh unknown
- 2024-09-12 US US18/882,822 patent/US20250084056A1/en active Pending
- 2024-09-12 PT PT247827116T patent/PT4587429T/pt unknown
- 2024-09-12 EP EP24782711.6A patent/EP4587429B1/en active Active
- 2024-09-12 WO PCT/US2024/046299 patent/WO2025059245A1/en active Pending
- 2024-09-12 MA MA72090A patent/MA72090B1/fr unknown
- 2024-09-12 AR ARP240102427A patent/AR133800A1/es unknown
- 2024-09-12 DK DK24782711.6T patent/DK4587429T3/da active
- 2024-09-12 KR KR1020257012489A patent/KR20250068738A/ko active Pending
- 2024-09-12 JP JP2025528339A patent/JP7808733B2/ja active Active
-
2026
- 2026-02-27 CO CONC2026/0002534A patent/CO2026002534A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022152822A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| WO2023059609A1 (en) | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023069720A1 (en) | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FI4587429T3 (fi) | 2026-03-24 |
| MA72090B1 (fr) | 2026-03-31 |
| AR133800A1 (es) | 2025-11-05 |
| PT4587429T (pt) | 2026-03-20 |
| KR20250068738A (ko) | 2025-05-16 |
| US20250084056A1 (en) | 2025-03-13 |
| WO2025059245A1 (en) | 2025-03-20 |
| DK4587429T3 (da) | 2026-03-30 |
| CO2026002534A2 (es) | 2026-03-16 |
| EP4587429B1 (en) | 2026-02-18 |
| TW202525792A (zh) | 2025-07-01 |
| JP2026500094A (ja) | 2026-01-06 |
| EP4587429A1 (en) | 2025-07-23 |
| LT4587429T (lt) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114302884B (zh) | 可作为t细胞活化剂的经取代吡啶并嘧啶酮基化合物 | |
| US10214540B2 (en) | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| CN114466849B (zh) | 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物 | |
| JP2021529191A (ja) | Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 | |
| JP2021514982A (ja) | インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用 | |
| CN108290871A (zh) | 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂 | |
| US10875863B2 (en) | RIPK2 inhibitors and method of treating cancer with same | |
| TW201726647A (zh) | 醫藥化合物 | |
| KR20230165815A (ko) | 피리디닐 치환된 옥소이소인돌린 화합물 | |
| CN112739420A (zh) | 苯氧基-吡啶基-嘧啶化合物及使用方法 | |
| TW202333663A (zh) | Rxfp1促效劑 | |
| JP7808733B2 (ja) | 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物 | |
| CN103261193A (zh) | 抑制白三烯生成的*二唑抑制剂 | |
| CN109476638B (zh) | 吡唑衍生物、其组合物及治疗用途 | |
| TW202525802A (zh) | 經取代之苯基氧代㗁唑基哌啶二酮化合物 | |
| CA3149302A1 (en) | Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| AU2024281056A1 (en) | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins | |
| HK40126737A (zh) | 抗病毒吡唑并吡啶酮化合物 | |
| HK40051446A (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
| HK40127606A (zh) | 经取代的苯基恶唑酮化合物 | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| HK40069881B (zh) | 抗病毒吡唑并吡啶酮化合物 | |
| EA048753B1 (ru) | Пиридинилзамещенные оксоизоиндолиновые соединения | |
| HK40113963A (zh) | Pd-1/pd-l1抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250610 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250610 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250610 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251223 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7808733 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |